The Min Lu Research Group

Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
State Key Laboratory of Omics and Disease (formerly State Key Laboratory of Medical Genomics)

The Min Lu Research Group

Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
State Key Laboratory of Omics and Disease (formerly State Key Laboratory of Medical Genomics)

Research Direction 1: “From 0 to 1” Targeted Anticancer Protein

Background: In clinical oncology, there are about 80 approved small-molecule targeted drugs. Most of them target oncoproteins whereas none targets tumor suppressor (the below figure). Mechanistically, a oncoprotein-targeting drug just need to inhibit protein function, with the molecular mechanisms of how a small molecule binds and inhibits protein is clear and understandable. However, a tumor […]

Research direction-2: drugging ‘smooth’ proteins without druggable pockets

Background: Among the 568 established therapeutical anticancer targets (Martinez-Jimenez, Nat Rev Can, 2020, 20, 555-572), a small number of them are overlappingly drugged (29/568; ~5%) whereas the vast majority of them remain “undruggable” (539/569; ~95%; the below figure). Mechanistically, the most of the drugged targets are kinases because they have a deep and narrow pocket for small […]